COVID-19. More research is undoubtedly needed before definitive recommendations about the routine use of n-3 PUFAs in the context of COVID-19 can be made particularly that dosing data and pharmacokinetics studies of both enteral and parenteral n-3 PUFAs in critically ill patients are highly variable and incomplete.

10  Summary and conclusion
In summary, COVID-19 is rapidly spreading around the globe and our understanding of the virus is limited. To date, th